Ropes & Gray LLP is notably active in the life sciences sector, working with clients such as TRexBio, Abata Therapeutics, and Pfizer Ventures. The firm is experienced in guiding emerging companies and investors through the complexities of early, growth, and late-stage venture financings. The group is also able to support clients with complex regulatory and compliance challenges and advised IDRx on securing license agreements as part of a $122m Series A financing. The practice is co-led by Bradford Flint and Marc Rubenstein from Boston, who specialize in serving biotech, pharmaceutical, and medical device clients on formations, intellectual property licensings, and devising exit strategies. In San Francisco, Melissa Bender spearheads the firm’s crypto blockchain task force and offers her expertise to both US and international institutional investors.
Key clients
- Canopy Capital (fka GoldenX)
- Filecoin Foundation for the Decentralized Web – Starling Lab
- TRexBio
- Abata Therapeutics
- Lytica Therapeutics
- Aera Therapeutics
- Term Labs
- StorageChain
- SoV0
- Solarea Bio
- Collab Fund
- Pfizer Inc.
- Sands Capital Management
- TPG Capital
- NewPath Partners
- RTW Investments
- Novalis LifeSciences
- Bain Capital
Work highlights
- Facilitated a deal for TRexBio with Eli Lilly, securing a $55m upfront payment and potential for over $1.1bn in milestones for novel immune therapy developments.
- Assisted Aera Therapeutics' spin-out from the Broad Institute, securing $193m in Series A funding to advance in-licensed technologies.
- Supported Bain Capital Tech Opportunities in a $190m investment in Blackpoint Cyber to enhance cybersecurity technology and MSP capabilities against evolving threats.
Practice head
The lawyer(s) leading their teams.
Bradford Flint, Marc Rubenstein